Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: J Am Acad Child Adolesc Psychiatry. 2011 Aug 5;50(9):915–924. doi: 10.1016/j.jaac.2011.06.009

Table 2.

Mean weeks in study by study end point

Risperidone (R) (N=18) Placebo (PL) (N=22) p-value for
number of weeks
in study for each
end point, R vs.
PL
N (%) Mean weeks in
study (SD)		 N (%) Mean weeks in
study (SD)
Reach target weight and maintain for 1 month 6 (33%) 10.0 (2.7) 10 (45%)   9.5 (3.3) 0.76
Worsening anorexia nervosa symptoms and 2 weeks of weight loss 2 (11%) 9.0 (2.8) 3 (14%)   6.7 (3.5) 0.50
Medical complications or side effects 1 (6%) 9.0      0 N/A
Patient request to end study 7 (39%) 5.6 (4.1) 6 (27%)   8.7 (2.4) 0.14
At maximum titration dose for 4 weeks without consistent weight gain 2 (11%) 14.0 (4.2) 3 (14%) 12.7 (2.1) 0.66